New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
09:45 EDTMYL, PRGOMylan would be a good target for Perrigo, dealReporter says citing source
A banker considers Mylan a good target for Perrigo and believes the company is reconsidering big deals, says dealReporter.
News For PRGO;MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
10:43 EDTMYLMylan calls active after called 'most likely' Pfizer takeover target
Subscribe for More Information
10:34 EDTMYLMylan advances after called 'most likely' Pfizer takeover target
Subscribe for More Information
07:48 EDTMYLMylan now most likely takeover target for Pfizer, says Jefferies
Jefferies believes Mylan (MYL), following its combination with Abbott's (ABT) Developed Markets Established Products business, is now the most likely takeover target of Pfizer (PFE). The firm thinks Pfizer management is highly motivated to either merge with, invert into or acquire a foreign company. It believes Actavis (ACT) and AstraZeneca (AZN) are off the table as potential Pfizer targets given the former's takeover of Allergan (AGN) and latter's oncology deal with Merck KGaA (MKGAY). Jefferies calls GlaxoSmithKline (GSK) the "wild card" potential takeover target for Pfizer. The firm estimates Pfizer could pay a 25% premium for Mylan and have the deal be highly accretive.
November 25, 2014
07:33 EDTMYLMylan sued by Baxter in connection with ANDA for Esmolol HCl
Subscribe for More Information
November 24, 2014
07:57 EDTPRGOPerrigo confirms first to file patent challenge for generic version of Aveed
Subscribe for More Information
07:53 EDTPRGOPerrigo announces launch of generic version of Astellas' Protopic ointment
Perrigo announced that it has agreed to market the authorized generic version of Astellas U.S. LLC's' Protopic Ointment 0.1% and 0.03%. Shipments to our pharmacy customers have commenced. Protopic Ointment is indicated to treat moderate to severe eczema. Brand sales were approximately $176M over the last 52 weeks according to Symphony Health Solutions.
November 21, 2014
14:17 EDTPRGOPerrigo price target raised to $184 from $175 at CRT Capital
Subscribe for More Information
10:20 EDTPRGOHigh option volume stocks
Subscribe for More Information
November 20, 2014
20:07 EDTPRGOPerrigo 5.92M share Secondary priced at $152.00
Subscribe for More Information
10:33 EDTPRGOHigh option volume stocks
High option volume stocks: KBR LM PRGO CHRW DG ZMH LGF ZTS OSIR REGI
06:56 EDTPRGOPerrigo files to sell $900M in ordinary shares
Perrigo intends to use the net proceeds of the offering, together with the proceeds of other financing sources, to fund the cash consideration for its proposed acquisition of Omega Pharma Invest NV and to repay or refinance certain indebtedness of Perrigo and/or Omega. If the Acquisition is not consummated, then the net proceeds of the offering will be used for general corporate purposes. J.P. Morgan, Barclays and BofA Merrill Lynch are the joint book-running managers in the offering.
06:56 EDTPRGOPerrigo files automatic mixed securities shelf
Subscribe for More Information
November 19, 2014
10:14 EDTMYLMylan November calls active on takeover speculation
Mylan November 55 & 57.5 calls are active on total call volume of 7,100 contracts (200 puts) on takeover speculation. November call option implied volatility is at 36, December is at 34; compared to its 26-week average of 32 according to Track Data. Active call volume suggests traders taking positions for upside price movement.
09:51 EDTMYLRumor: Mylan strength attributed to takeover speculation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use